» Articles » PMID: 19995915

MTORC1-activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates MTORC2 Signaling

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2009 Dec 10
PMID 19995915
Citations 233
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian target of rapamycin (mTOR) is a conserved Ser/Thr kinase that forms two functionally distinct complexes important for nutrient and growth factor signaling. While mTOR complex 1 (mTORC1) regulates mRNA translation and ribosome biogenesis, mTORC2 plays an important role in the phosphorylation and subsequent activation of Akt. Interestingly, mTORC1 negatively regulates Akt activation, but whether mTORC1 signaling directly targets mTORC2 remains unknown. Here we show that growth factors promote the phosphorylation of Rictor (rapamycin-insensitive companion of mTOR), an essential subunit of mTORC2. We found that Rictor phosphorylation requires mTORC1 activity and, more specifically, the p70 ribosomal S6 kinase 1 (S6K1). We identified several phosphorylation sites in Rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner. Phosphorylation of Rictor on Thr1135 did not affect mTORC2 assembly, kinase activity, or cellular localization. However, cells expressing a Rictor T1135A mutant were found to have increased mTORC2-dependent phosphorylation of Akt. In addition, phosphorylation of the Akt substrates FoxO1/3a and glycogen synthase kinase 3 alpha/beta (GSK3 alpha/beta) was found to be increased in these cells, indicating that S6K1-mediated phosphorylation of Rictor inhibits mTORC2 and Akt signaling. Together, our results uncover a new regulatory link between the two mTOR complexes, whereby Rictor integrates mTORC1-dependent signaling.

Citing Articles

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

Middleton G, Robbins H, Fletcher P, Savage J, Mehmi M, Summers Y NPJ Precis Oncol. 2025; 9(1):67.

PMID: 40069402 PMC: 11897347. DOI: 10.1038/s41698-025-00838-4.


Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.

PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.


Screening high-risk individuals for primary gastric adenocarcinoma: evaluating progression-free survival probability score in the presence and absence of Rictor expression after gastrectomy.

Wang J, Li Y, Liang S Front Oncol. 2024; 14:1382818.

PMID: 39588299 PMC: 11586260. DOI: 10.3389/fonc.2024.1382818.


Effects of Target of Rapamycin and Phosphatidylinositol 3-Kinase Inhibitors and Other Autophagy-Related Supplements on Life Span in Male .

Bearden A, Stewart E, Casher C, Shaddix M, Nobles A, Mockett R Int J Mol Sci. 2024; 25(21).

PMID: 39519056 PMC: 11547029. DOI: 10.3390/ijms252111504.


CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation.

OSullivan P, Aidarova A, Afonina I, Manils J, Thurston T, Instrell R Biochem J. 2024; 481(18):1143-1171.

PMID: 39145956 PMC: 11555713. DOI: 10.1042/BCJ20240058.


References
1.
Manning B . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(3):399-403. PMC: 2172491. DOI: 10.1083/jcb.200408161. View

2.
Shiota C, Woo J, Lindner J, Shelton K, Magnuson M . Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell. 2006; 11(4):583-9. DOI: 10.1016/j.devcel.2006.08.013. View

3.
Tee A, Manning B, Roux P, Cantley L, Blenis J . Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003; 13(15):1259-68. DOI: 10.1016/s0960-9822(03)00506-2. View

4.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B . Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009; 136(3):521-34. PMC: 3733119. DOI: 10.1016/j.cell.2008.11.044. View

5.
Choo A, Yoon S, Kim S, Roux P, Blenis J . Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008; 105(45):17414-9. PMC: 2582304. DOI: 10.1073/pnas.0809136105. View